SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : 10-Bagger MINIMUM Rise from July 1, 2005 until December 31,

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Walkingshadow who wrote (757)11/2/2005 8:41:32 PM
From: jmhollen  Read Replies (2) of 1694
 
It's a little odd that you would press that point so strenuously. It would appear that Dr. Diwan, PhD is reasonably well qualified, unless someone has some specific information contrary to what is published. Have you run across something in your readings, studies, or work to indicate that..???

Anil R. Diwan, PhD, President, Inventor of TheraCour technology that enables NanoViricides drugs.

Dr. Diwan has extensive product development experience while raising financing from collaborations, SBIR grants, other revenues. He has extensive experience in a number of bio-pharmaceutical, biosciences, and biomedical fields and technologies that leads to his novel, integrative approach in solving problems with low costs, high innovation, and world-leading feature sets. Dr. Diwan is the inventor, developer, and principal investor of TheraCour technologies. The nanomaterials based on these technologies form the basis of nanoviricides drugs.

Anil holds a US patent on his older polymeric micelle technologies, with his colleagues at University of Massachusetts. He has continued to work further in the field, to develop nanomaterials that are capable of multi-specific multi-targeting of viruses, and at the same time capable of encapsulating active pharmaceutical ingredients (API) in industry-leading payload capacities. This new work has resulted in nanomaterials called "TheraCour" (therapeutic courier), and the underlying technology is subject of a new patent application. Multi-targeting allows binding to the virus particle like a Velcro tape, and Multi-specificity allows highly selective binding to a specific type of virus. The encapsulated API can get injected into the virus particle.

Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Bombay (IIT-B), India, and has consistently held high scholastic ranks and honors. Anil has over 18 years of Bio-Pharmaceuticals R&D experience with 12 years as an entrepreneur.


If you have a link to some data that disputes the above info, I'd be pleased to go read it. I haven't found any so far. Rice U. has never been accused of being a diploma mill to my knowledge and India is doing pretty well in the medical fields these days, from what I've seen on TV.

John :-)

.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext